Valeritas (NASDAQ:VLRX) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.
Valeritas (VLRX) opened at $3.09 on Friday. The company has a debt-to-equity ratio of 3.54, a current ratio of 3.88 and a quick ratio of 3.20. Valeritas has a 1 year low of $2.00 and a 1 year high of $40.00.
Valeritas (NASDAQ:VLRX) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($1.62) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.84) by $0.22. Valeritas had a negative return on equity of 820.08% and a negative net margin of 229.55%. equities analysts anticipate that Valeritas will post -8.31 EPS for the current year.
Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.